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Abstract
Limb-girdle muscular dystrophy types 2D and 2F (LGMD 2D and 2F) are autosomal reces-
sive disorders caused by mutations in the alpha- and delta sarcoglycan genes, respectively,
leading to severe muscle weakness and degeneration. The cause of the disease has been
well characterized and a number of animal models are available for pre-clinical studies to
test potential therapeutic interventions. To facilitate transition from drug discovery to clinical
trials, standardized procedures and natural disease history data were collected for these
mouse models. Implementing the TREAD-NMD standardized operating procedures, we
here subjected LGMD2D (SGCA-null), LGMD2F (SGCD-null) and wild type (C57BL/6J)
mice to five functional tests from the age of 4 to 32 weeks. To assess whether the functional
test regime interfered with disease pathology, sedentary groups were taken along. Muscle
physiology testing of tibialis anterior muscle was performed at the age of 34 weeks. Muscle
histopathology and gene expression was analysed in skeletal muscles and heart.
Muscle histopathology and gene expression was analysed in skeletal muscles and heart.
Mice successfully accomplished the functional tests, which did not interfere with disease
pathology. Muscle function of SGCA- and SGCD-null mice was impaired and declined over
time. Interestingly, female SGCD-null mice outperformed males in the two and four limb
hanging tests, which proved the most suitable non-invasive tests to assess muscle function.
Muscle physiology testing of tibialis anterior muscle revealed lower specific force and higher
susceptibility to eccentric-induced damage in LGMD mice. Analyzing muscle histopathology
and gene expression, we identified the diaphragm as the most affected muscle in LGMD
strains. Cardiac fibrosis was found in SGCD-null mice, being more severe in males than in
females. Our study offers a comprehensive natural history dataset which will be useful to
design standardized tests and future pre-clinical studies in LGMD2D and 2F mice.
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Introduction
Muscular dystrophies are a group of inherited, heterogeneous muscle disorders characterized
by progressive muscle weakness and degeneration. The pattern of muscle weakness varies both
in distribution and severity and underlies the subdivision into several disease types: Duchenne
and Becker, Emery-Dreifuss, distal, facioscapulohumeral, oculopharyngeal, and limb-girdle
muscular dystrophies [1]. The limb-girdle muscular dystrophies (LGMDs) involve a slowly
progressive weakening of proximal muscles of the hip and shoulder girdles. LGMD is the most
heterogeneous collection of muscular dystrophies with over 30 LGMD subtypes identified
according to their genetic defects with autosomal dominantly and recessively inherited
LGMDs subgrouped as LGMD1 and LGMD2, respectively. Sarcoglycanopathies are one of the
more common forms of autosomal recessive LGMD and comprise four subtypes: LGMD2C,
-D, -E and -F. They are caused by mutations in the genes coding for the muscle-specific trans-
membrane sarcoglycan proteins α-, β-, γ-, and δ-sarcoglycan. These sarcoglycans form a cru-
cial component of the dystrophin-glycoprotein complex (DGC). The DGC is a large complex
of membrane-associated proteins that further consists of dystrophin, the dystroglycans (α and
β), sarcospan, the syntrophins (α1, β1, β2, γ1- and γ2) and α-dystrobrevin [2]. This complex
physically links the intracellular cytoskeleton to the extracellular matrix. The loss of this struc-
tural connection, for instance due to mutations in one of the sarcoglycans, makes muscle fibers
more susceptible to damage during muscle contraction [2–5].
Although the causative gene mutations are well characterized, there is no therapy available
for sarcoglycanopathies [6]. Still, animal models for α- and δ-sarcoglycanopathies (LGMD
types 2D and 2F) that recapitulate many features of human disease have been developed and
are suitable for pre-clinical research [7, 8]. Although there is a growing demand for pre-clinical
testing, there is a lack of generally accepted pre-clinical outcome measures and lack of natural
history data for these outcome measures. Therefore, an international effort was initiated by the
TREAT-NMD network and the Wellstone Center with the aim to develop standardized proce-
dures focusing on pre-clinical models for Duchenne muscular dystrophy and spinal muscular
dystrophy. These standardized procedures are used worldwide and permit more direct com-
parison of pre-clinical drug testing between laboratories (http://www.treat-nmd.eu/research/
preclinical/overview/). There is a lack of natural history data and clearly defined outcome mea-
sures for LGMD mouse models.
Therefore, in the present study, we characterized the natural disease history of LGMD2D
and 2F (SGCA- and SGCD-null) mice [9, 10] using standardized operating procedures avail-
able from the TREAD-NMD network for the mdx mouse model, which has a comparable phe-




The SGCA-null (B6.129S6-Sgcatm2Kcam/J, α-deficient) mice [9] were kindly provided by
Queensta Millet, University College London and the SGCD-null (B6.129-Sgcd tm1Mcn/J, δ-defi-
cient) mice [10] were obtained from Jackson Laboratory (Bar Harbor, ME, USA) and bred in
the Experimental Animal Facility of the Leiden University Medical Center. All mice used in
this study were on a C57BL/6J background and were compared to C57BL/6J wild type mice.
Mice were kept in individually ventilated cages with 12 hours of light/dark cycles at 20.5˚C
and had ad libitum access to standard RM3 chow (SDS, Essex, UK) and water. All experiments
were approved by and performed following the guidelines of the Animal Experiment
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Committee (DEC 13211) of the Leiden University Medical Center. Care was taken to limit the
burden and distress for the animals as much as possible.
Functional test regime
SGCA-null and SGCD-null mice (12 mice per genotype; 6 males and 6 females) were ran-
domly assigned to either a functionally challenged or unchallenged group. Wild type mice
(C57BL/6J) (12 mice; 6 males and 6 females) were assigned to the functionally challenged
group only, as the functional test regime is not detrimental to wild type mice [11]. Functionally
challenged mice were subjected to a functional test regime consisting of five functional tests
performed on consecutive days, from the age of 4 to 34 weeks twice monthly. Body weight was
recorded at the start of each functional test regime session. Functional tests aimed to assess
muscle function, strength, coordination and condition. An overview of the experimental time-
lines is given in the S1 Fig. Standardized operating procedures from the TREAT-NMD net-
work were implemented when possible [12]. All experiments were performed blinded to avoid
biased results.
Four limb grip strength test. Peak force of the fore and hind limbs was measured using a
grid attached to an isometric force transducer (Columbus Instruments, USA). Hereto, the
mouse was suspended, handled by the tail, above the grid which it naturally grasped with its
four paws. It was then pulled from the grid. The maximal force applied by the mouse when
pulled from the grid was recorded by the force transducer. This test was repeated three times
in a row after which the mouse was allowed a short rest. The mouse was suspended to five
series of three pulls, each followed by a resting period. In this way the mouse was pulled in
total 15 times. The three highest values out of the 15 values obtained were averaged and the
maximum grip strength was calculated and normalized to body weight.
Rotarod. Motor coordination and balance were assessed with rotarod running. The
mouse was placed on the rotarod (Ugo Basile, Italy) that accelerated from 5 to 45 rotations per
minute within 15 seconds. The time it took mice to fall off the rod was recorded. The test ses-
sion was completed when the mouse had run for 500 seconds without falling. Mice that had
fallen off within 500 seconds were allowed two more tries. The longest running time was used
for analysis.
Two limb hanging test. The maximum hanging time with two limbs was assessed using a
previously described protocol [12]. The test ended after a hanging time of 600 seconds was
achieved or otherwise after three sessions. The maximum time score was used for analysis.
Four limb hanging test. The maximum hanging time with four limbs was performed
using a previously described protocol [12].The test ended after a hanging time of 600 seconds
was achieved or otherwise after three sessions. The maximum hanging time was used for
analysis.
Beam walk test. The mouse was placed on an elevated narrow beam (diameter 11mm)
and had to walk across to a safe black box, while being filmed. Performance on the beam was
quantified by the time it took to traverse the 80 cm long beam and the numbers of hind paw
slips that occurred during beam walking. The mice were allowed three tries. The traverse times
and numbers of paw slips were averaged.
Respiratory function analysis
All mice underwent respiratory function analysis with whole-body plethysmography [13]
(RM-80; Columbus Instruments, Columbus, OH, USA) at the ages of 15 and 34 weeks. After
30 seconds acclimatization, the respiration signal was recorded for 120 seconds. The signal
was digitized using a Minidigi digitizer and AXOSCOPE 10 software (Axon Instruments/
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Molecular Devices, Sunnyvale, CA, USA) and analysed with the event detection feature of the
Clampfit 10 program (Axon Instruments/Molecular Devices). This non-invasive monitoring
system provided breathing function analysis measuring respiration rate and depth. The respi-
ration signal amplitude was normalized to body weight.
Creatine kinase level analysis
Monthly before performing functional tests, blood was taken via a small angled cut in the tail
and collected in heparin coated microvettes (Sarstedt B.V. the Netherlands) and stored on ice.
To separate plasma, the blood was centrifuged at 4˚C for five minutes at 13000 RPM. Plasma
creatine kinase (CK) levels were measured with Reflotron CK test strips in the Reflotron plus
machine (Roche Diagnostics Ltd., UK).
In vivo force measurements of tibialis anterior muscles
At 34 weeks of age, each mouse was anesthetized with 2% isoflurane and function of the right
tibialis anterior muscle was assessed using previously described protocol [14]. In short, after
mice were surgically prepared, muscles underwent a warm up protocol (five stimulations of 50
Hz spaced one minute apart). Thereafter, the maximum isometric tetanic force (Po) was deter-
mined from the plateau of the force—frequency relationship following a series of stimulations
at 10, 30, 40, 50, 80, 100, 120, 150 and 180 Hz. The specific force (N/cm2) was determined by
dividing Po by the muscle cross-sectional area. The overall cross-sectional area was calculated
using the formula: muscle weight (g)/ [tibialis anterior fiber length (Lf; cm) × 1.06 (g/cm3)].
The specific isometric force was determined by dividing the absolute force at each stimulation
frequency by the muscle’s cross sectional area. After five minutes, susceptibility to contraction-
induced injury was measured. To this end, muscles were stimulated at 120 Hz for 500 ms
before lengthening at 10% of Lo at a velocity of 0.5 Lo s
-1. At the end of the stimulation session,
the muscle was returned to Lo at a rate of −0.5 Lo s-1. The stimulation-stretch cycle was
repeated every two minutes to a total of ten cycles. The maximum isometric force of the first
contraction served as the 100% baseline. After the procedure, the muscles were isolated,
weighed and prepared for histological and gene expression analyses.
Muscle histology and morphology
Frozen muscle sections (8 μm thick) were cut with a cryotome and intermediate sections were
collected for RNA isolation. Slides were fixed in ice-cold acetone for five minutes, stained with
hematoxylin and eosin (Sigma-Aldrich, Zwijndrecht, the Netherlands) and mounted in Per-
mount mounting medium (Histolab, Västra Frölunda, Sweden), according to conventional
methods. To localize and quantitate lipid droplets, muscle sections were stained with Nile red
(9-diethylamino-5H-benzo(alpha)phenoxazine-5-one) staining (Thermo fisher scientific,
Breda, the Netherlands) [15]. Non-fixed muscle sections were air dried, washed with PBS/
Tween 0.05%, incubated in 1 μmol Nile red solution for 15 minutes and rinsed three times in
PBS/Tween 0.05%. Sections were mounted with mounting medium with DAPI (ProLong
Antifade Reagents; Life Technologies, Bleiswijk, the Netherlands) and imaged with an AF6000
(Leica) and BZ-X700 fluorescent microscopes (Keyence, Osaka, Japan) at ten times magnifica-
tion. The percentage of fat accumulation of the entire muscle was quantified with ImageJ by
dividing the area occupied with fat droplets by the total tissue area. For the fiber size distribu-
tion analyses, muscle sections were stained with a laminin primary antibody (ab11575, dilution
1:200 Abcam, USA) and with a goat-anti-rabbit Alexa 594 secondary antibody (A11012, dilu-
tion 1:1000, Life Technologies). The distribution was assessed with SMASH (Matlab based
analysis) as previously described [16]. Five microscopic views were analysed resulting in an
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average total number of 1500–3000 fibers per muscle measured and the number of fibers in a
given Feret’s diameter class (10 μm/class) was determined. To detect regenerative fibers, dia-
phragm muscle sections were stained with an eMHC primary antibody (F1.652, sc-53091 dilu-
tion 1:20, Santa Cruz Biotechnology, Inc) overnight at 4˚C and with a goat-anti-mouse Alexa
488 secondary antibody (A11001, dilution 1:1000, Life Technologies) and DAPI for 1.5 hours
at room temperature. Images of the stained muscle sections were taken with a BZ-X700 X700
fluorescent microscope (Keyence) at ten times magnification. For fibrotic area analyses, mus-
cle and heart sections were stained with collagen type I primary antibody (1310–01 Southern
Biotech, dilution 1:100, Birmingham, USA) overnight at 4˚C and with a donkey-anti-goat
Alexa 488 secondary antibody (A11001, dilution 1:1000, Life Technologies) and DAPI for
one hour at room temperature and mounted with mounting medium (ProLong Antifade
Reagents; Life Technologies). Images of the stained muscle and heart sections were taken with
a BZ-X700 X700 fluorescent microscope (Keyence) at ten times magnification and stitched
with the Leica software LASFx. Using ImageJ analysis the fibrotic areas were measured. The
percentage of fibrotic area was calculated by dividing the collagen type I positive area by the
total tissue area.
RNA isolation and, qPCR
Muscle sections were collected in 1.4 mm Zirconium Beads prefilled tubes (OPS Diagnostics,
Lebanon, USA) and homogenized in TriPure isolation reagent (Roche Diagnostics, Basel,
Switzerland) using a MagNA Lyser (Roche Diagnostics). Total RNA was isolated using the Tri-
Pure isolation method and the RNA was further cleaned up by applying a NucleoSpin RNA II
kit (Macherey-Nagel, Düren, Germany) according to the manufacturer’s instruction. cDNA
was synthesized from 0.4–1 μg of RNA (depending on the muscle type but kept constant
between comparisons) using random N6 primers (Thermo fisher scientific) and Bioscript
enzyme (GCBiotech, Alphen aan den Rijn, the Netherlands) according to the manufacturer’s
instructions. Quantitative PCR was performed in triplicate per biological sample using a Light-
Cycler 480 and ready-to-use SensiMix reagents (GCBiotech). The expression levels were ana-
lysed with the LinReg qPCR method and normalized to expression values of the housekeeping
gene Gapdh. Primer sequences and detailed PCR conditions can be provided on request.
Statistical analyses
Data were analysed by using Prism 4 (GraphPad Software, La Jolla, CA, USA) and SPSS 17.0.2
(IBM, Armonk, NY, USA). Values are presented as means ±SD or ±SEM. A linear regression
model was applied to compare the maximum hanging times of the hanging tests and the maxi-
mum running times from the rotarod tests over age per mouse per genotype. Area under
curve (AUC) values were calculated for grip strength, CK levels, traverse latency and number
of hind limb slips from beam walk test over age per mouse per genotype and then compared
between genotypes with a one-way ANOVA test. Respiration amplitudes and rates were com-
pared between genotypes using mixed models. For physiological analyses of tibialis anterior
muscles, AUCs were calculated for the specific force over frequency per genotype and the ini-
tial force drop over number of contraction per genotype and compared between genotypes
with a one-way ANOVA test. To compare maximal hanging time between genders, AUCs
were calculated over age per mouse per gender and compared between genders with a one-
way ANOVA test. Results of histological and gene expression analyses were compared between
genotypes using a two-way ANOVA test and corrected for multiple comparisons with Tukey’s
multiple comparison test. Fiber size distribution was assessed using logistic regression with
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SPSS to demonstrate the switch toward smaller fiber sizes for SGCA- and SGCD-null mice.
Statistical significance was set at P< 0.05. SPSS statistics syntax can be provided on request.
Results
Impaired muscle function and muscle integrity in LGMD strains
SGCA-, SGCD-null and wild type mice were subjected twice monthly to a functional test
regime from 4 until 32 weeks of age. The functional test regime consisted of five different func-
tional tests: four limb grip strength, rotarod running, two and four limb hanging tests and
beam walk test.
Since experimental groups consisted of six male and female mice, we could study differ-
ences in muscle performance not only between strains but also between genders. In the four
limb grip strength test that served to assess muscle strength and function, the normalized grip
strength did not differ either between strains or genders. However, combining male and
female data resulted in a significant decrease in the normalized grip strength in SGCD-null
mice when compared to SGCA-null and wild type mice over time (Fig 1a and S2a Fig). In the
rotarod test, which examines coordination and endurance, both SGCA- and SGCD-null mice
had a shorter running time than had wild type mice, but this did not reach significance due to
high inter- individual variation in wild type mice (S2b Fig). Muscle strength and fatigability
were tested using two and four limb hanging tests. Interestingly, female SGCD-null mice sig-
nificantly outperformed male mice in two and four limb hanging tests, while no difference
between genders was observed for SGCA-null or wild type mice (Fig 1b and 1c and S2c and
S2d Fig). Moreover, SGCA- and male SGCD-null mice hung for a significantly shorter time
period than did wild type mice in both tests (Fig 1b and 1c and S2c and S2d Fig). In contrast to
the four limb grip strength data, combined data revealed that SGCA-null mice performed sig-
nificantly worse in the hanging tests than did SGCD-null mice (S2c and S2d Fig), which can be
explained by the better performance of SGCD females. In the two limb hanging test, the
performance of both LGMD strains notably deteriorated over time (Fig 1b and S2c Fig). In
addition, the performance of SGCA-null mice significantly declined over time in four limb
hanging test, whereas there was no significant decline in SGCD-null mice (Fig 1c and S2d Fig).
Muscle coordination and the ability to balance was assessed with the beam walk test (S2e and
S2f Fig). The traverse times and numbers of paw slips were lower at baseline and increased
over time in LGMD mice compared to wild type mice. Due to high inter-individual variation,
differences did not reach significance.
Body weight and plasma CK levels were assessed longitudinally. No differences were found
in body weights between LGMD and wild type mice (S2g Fig). SGCA- and SGCD-null mice
had significantly higher plasma CK levels than wild type mice (<500 U/L). CK levels neither
differed between the LGMD strains nor between female and male mice (Fig 1d).
As diaphragm muscle can be severely affected in dystrophic mouse models, we measured
respiratory function with whole-body plethysmography in mice aged 15 and 34 weeks. While
the respiration amplitude was similar across wild type, SGCA- and SGCD-null mice (Fig 1e),
both SGCA- and SGCD-null mice showed significant lower respiration rates than did wild
type mice at 15 and 34 weeks of age (Fig 1f). Similar to the hanging tests data, the respiration
rate was significantly lower in SGCA- than in SGCD-null mice. However, the respiration
amplitude and rate did not differ between genders.
We performed tibialis anterior physiology analysis with a focus on force-frequency relation-
ship and resistance to eccentric contraction at 34 weeks of age. The force-frequency curve of
fast-twitch tibialis anterior muscles stayed flat and rose rapidly from 50 Hz onward. The tibialis
anterior muscles of SGCA- and SGCD-null mice generated a significantly lower specific force
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Fig 1. Impaired muscle function and integrity in SGCA- and SGCD-null mice. (a) Normalized four limb grip strength was
significantly lower in SGCD-null mice than in wild type and SGCA-null mice (b) Maximum hanging time with two limbs was
significantly shorter in SGCA- and SGCD-null mice when compared to wild type mice. SGCD-null mice outperformed SGCA-null
mice. Maximum hanging time was significantly shorter in male SGCD-null mice than in female SGCD-null mice. (c) Maximum
hanging time with four limbs was significantly shorter in SGCA- and SGCD-null mice when compared to wild type mice. SGCD-null
Natural disease history of mouse models for limb girdle muscular dystrophy types 2D and 2F
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than those of wild type mice over a wide range of stimulation intensities (10–180 Hz) (Fig 1g).
Unlike with the hanging tests, the specific force was comparable between males and females
from the same strain. Furthermore, SGCD-null muscles generated a significantly lower specific
force than SGCA-null muscles. We also measured the tibialis anterior muscle’s response to
eccentric contraction, which can induce injury in dystrophic muscle fibers [17]. Tibialis ante-
rior muscles were repetitively stimulated at 120 Hz and stretched to 110% of their resting
length. While the isometric force significantly dropped by 10–15% in SGCA- and SGCD-null
mice, it remained unchanged in wild type mice (Fig 1h). Similar to the specific force data, the
isometric force measurements did not differ between genders from the same strain.
To summarize, mice successfully accomplished the functional test regime suggesting that it
is suitable to use for both LGMD strains. Muscle function of SGCA- and SGCD-null mice was
impaired and declined over time. In both hanging tests, marked differences in performance
were detected in LGMD relative to wild type mice, while no differences were found in the
rotarod and beam walk tests due to large inter-individual variation. Female SGCD-null mice
outperformed males in the two and four limb hanging tests, while this was not the case for
SGCA-null and wild type mice.
Histological examination and gene expression analyses
Shift towards smaller fibers in LGMD muscles. A hallmark of muscular dystrophy is a
high proportion of smaller, regenerative muscle fibers due to cycles of de- and regeneration in
patients [18]. To assess fiber size distribution in our animal models, we measured the fiber’s
minimal Feret’s diameter in the gastrocnemius, tibialis anterior and diaphragm of LGMD and
wild type mice. As expected, the majority of fibers (35–40% depending on the muscle) of
SGCA- and SGCD-null mice consisted of smaller fibers with a minimal Feret’s diameter
between 5–20 μm (Fig 2a). In contrast, in wild type mice the majority of fibers (30–55%
depending on the muscle) consisted of fibers with a minimal Feret’s diameter between 21–
40 μm, while only less than 5% of their muscles contained small fibers. Unlike with the hanging
tests, the fiber size distribution did not significantly differ between SGCD-null males and
females.
Increased expression of regeneration markers in LGMD muscles. To detect regenera-
tive fibers, we performed embryonic myosin heavy chain (eMHC) staining in diaphragm mus-
cle from wild type, SGCA- and SGCD-null mice. As expected, diaphragm of SGCA- and
SGCD-null mice contained higher levels of eMHC when compared to wild type mice (Fig 2b).
To further validate increase in muscle regeneration, we measured gene expression of myogenic
markers embryonic myosin heavy chain (Myh3), myogenin (Myog), signal transducer and acti-
vator of transcription 3 (Stat3) and myogenic differentiation (Myod). As expected, wild type
muscles expressed very low levels of these markers, while SGCA- and SGCD-null muscles
mice outperformed SGCA-null mice. Maximum hanging time was significantly shorter in male SGCD-null mice than in female SGCD-
null mice. (d) Creatine kinase levels were significantly elevated in both LGMD strains. (e) No significant differences were detected in
respiration amplitude between the mouse models. (f) Respiration rate was significantly decreased in SGCA- and SGCD-null mice at
15 and 34 weeks of age compared to wild type mice. At 15 and 34 weeks of age, SGCA-null mice showed significantly lower
respiration rate than SGCD-null mice. No differences were found between males (in blue) and females (in pink). (g) Force frequency
relationship of the tibialis anterior muscle. Each data point represents the force measured at each frequency. Muscles of both SGCA-
and SGCD-null mice showed a significantly lower specific force than those of wild type mice. SGCD-null muscles generated a
significantly lower specific force than those of SGCA-null mice. (h) Relative changes in tetanic force during eleven cycles of eccentric
contraction in tibialis anterior muscle. The tetanic tension developed during the first cycle was taken as 100%. The isometric force
significantly dropped by 10–15% in SGCA- and SGCD-null mice, while it remained unchanged in wild type mice. For e and f
* Indicates a significant difference from wild type (WT) controls. # Indicates a significant difference from SGCA-null mice. Error bars
represent standard error of the mean (± SEM).
https://doi.org/10.1371/journal.pone.0182704.g001
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Fig 2. Smaller fiber sizes and increased muscle regeneration in SGCA- and SGCD-null mice. (a) Fiber size distribution of skeletal
muscles of 34-week-old SGCA-null, SGCD-null and wild type mice. Values represent relative number of fibers in a given diameter class
(10 μm/class). The fiber size distribution was shifted to smaller fibers in SGCA- and SGCD-null mice when compared to wild type mice in
gastrocnemius, tibialis anterior and diaphragm muscles. Fiber size distribution did not differ between male and female SGCD-null mice. (b)
Immunofluorescent images of diaphragm muscles stained with embryonic myosin heavy chain (eMHC) (regenerative marker, green) and
laminin (extracellular matrix of muscle fibres, red) Scale bar: 100 μm. (c) Increase in myogenic gene expression (Myh3, Myog, Stat3 and
Natural disease history of mouse models for limb girdle muscular dystrophy types 2D and 2F
PLOS ONE | https://doi.org/10.1371/journal.pone.0182704 August 10, 2017 9 / 23
expressed higher levels (Fig 2c). The increases in Myog and Myh3 levels were found to be sig-
nificant for LGMD diaphragm muscles. Stat3 levels were increased to a similar extent in all
muscles, but were only significantly elevated in the gastrocnemius muscles of female SGCD-
null mice and the tibialis anterior muscles of SGCA-null mice. Similar to Myog and Myh3,
Myod was significantly increased in diaphragm muscles of LGMD mice, but also in gastrocne-
mius muscles of male SGCD-null mice. Unlike with the hanging tests, the myogenic gene
expression did not significantly differ between SGCD-null males and females (Fig 2c).
Elevated collagen levels in skeletal muscles and heart of LGMD mice. Another hallmark
of sarcoglycanopathy in patients is fibrosis, the ongoing replacement of the muscle by connec-
tive tissue accompanied by chronic inflammation [19]. Fibrosis in SGCA- and SGCD-null
mice was examined by looking at collagen type I (Col1a1) expression on protein and RNA lev-
els. Overall, muscles of LGMD strains contained extensive fibrotic infiltrates compared to wild
type mice, with the diaphragm being most affected (Fig 3a and 3b). Additionally, a significant
increase was detected in the quadriceps of female LGMD mice as well as in the tibialis anterior
muscles of female SGCD-null mice relative to wild type muscles. We also measured gene
expression of Col1a1 as a marker of fibrosis and cluster of differentiation 68 (Cd68) as a marker
of inflammation. Interestingly, the gastrocnemius and diaphragm muscles expressed signifi-
cantly higher Col1a1mRNA levels, while the quadriceps and tibialis anterior muscle showed a
non-significant elevation of Col1a1mRNA levels in both LGMD strains compared to wild type
mice (Fig 3c). Cd68mRNA levels were significantly increased in LGMD gastrocnemius, tibialis
anterior and male SGCD-null diaphragm muscles. In contrast to the hanging tests, no signifi-
cant differences in fibrosis and inflammation markers were detected between SGCD-null
males and females (Fig 3a–3c). In addition to progressive weakness and wasting of the proxi-
mal limb muscles, LGMD 2F patients often show cardiac involvement [7]. Therefore, by mea-
suring collagen type I positive areas in heart we studied whether SGCD-null mice develop
cardiomyopathy. As expected marked increase in Col1a1 was detected in hearts of SGCD-null
mice but it was not the case for SGCA-null and wild type mice (Fig 3d). We quantified Col1a1
positive areas for female and male SGCD-null mice. Notably, in line with the more impaired
skeletal muscle function in SGCD-null males, hearts from males contained significantly higher
collagen levels than those from SGCD-null females (Fig 3d and 3e).
Accumulation of fat infiltrates in muscles of LGMD mice. When we stained muscle sec-
tions with a haematoxylin and eosin staining, we observed round, drop-like, unstained spots
in LGMD muscles, but not in healthy muscles. Using Nile-red staining, we identified these
spots as infiltrated lipid droplets (Fig 4a) and quantified their abundance in both LGMD
strains and wild type mice. Overall, fat infiltrates were more abundant in gastrocnemius and
diaphragm than in quadriceps and tibialis anterior muscles of both LGMD strains. The Nile-
red positive areas in the gastrocnemius of SGCA-null mice and the diaphragm of SGCD-null
mice were significantly larger than in wild type mice (Fig 4b). To confirm our finding, we mea-
sured expression of adipogenic genes (Fig 4c). A significant increase of adiponectin (Adipoq),
which is exclusively expressed in adipose tissue, was observed in tibialis anterior muscles of
SGCA-null mice. To distinguish between white and brown adipocytes (key site of heat produc-
tion), uncoupling protein 1 (Ucp1) (expressed only in brown adipocytes) transcript levels were
measured. Ucp1 was not detectable in muscles of wild type and LGMD mice (data not shown)
Myod) measured by qPCR and normalized to Gapdh in skeletal muscles of 34-week-old SGCA-null, female and male SGCD-null mice when
compared to wild type mice (all n = 5 mice per group). Q, quadriceps; GC, gastrocnemius; TA, tibialis anterior; Dia, diaphragm. * Indicates a
significant difference from WT controls. # Indicates a significant difference from female SGCD-null mice Error bars represent standard
deviation (±SD).
https://doi.org/10.1371/journal.pone.0182704.g002
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Fig 3. Elevated collagen levels in skeletal muscles in SGCA- and SGCD-null mice and in the heart of
SGCD-null mice. (a) Immunofluorescent images of skeletal muscles stained with collagen type I (fibrotic
marker, green) and laminin (extracellular matrix of muscle fibres, red) Scale bar: 100 μm. (b) Quantification of
collagen type I positive area in skeletal muscles relative to wild type muscles. A significant increase in the
percentage of collagen type I positive area was found in diaphragm and quadriceps muscles of SGCA- and
SGCD-null mice, while no difference was found in the gastrocnemius. Tibialis anterior muscles of female SGCD-
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suggesting that observed fat droplets contained mostly white adipocytes. Moreover, we mea-
sured expression levels of genes that regulate metabolic processes in adipose tissues. Namely,
peroxisome proliferator-activated receptor gamma (Ppar-gamma), which is a regulator of adi-
pocyte differentiation, was significantly increased in diaphragm muscle of SGCA-null and
quadriceps of SGCD-null relative to wild type mice. Similarly to Ppar-gamma, adipose triglyc-
eride lipase (Atgl or Pnpla2) transcript levels were upregulated in diaphragm muscle of SGCA-
null relative to wild type mice. Lastly, hormone-sensitive lipase (Hsl), implicated in hydrolyzes
of triglycerides, was significantly higher expressed in SGCA-null diaphragm than in wild type
muscle. Although not all detected changes reached significance, the expression pattern of the
adipogenic genes was consistent in that the gene expression was increased in LGMD mouse
models compared to wild type controls.
MSTN and TGF-β signalling components contribute to disease pathology in LGMD
mice. Elevated activity of the transforming growth factor beta (TGF-β) superfamily contrib-
utes to the pathogenesis in various types of neuromuscular disorders by inhibiting muscle
repair and promoting an increase in fibrotic tissue formation [20]. We measured gene expres-
sions of TGF-β signalling components and muscle specific growth inhibitor myostatin in the
gastrocnemius and diaphragm muscles of SGCA- and SGCD-null mice. Diaphragm muscle of
both LGMD strains expressed significantly higher levels of three isoforms of Tgf-β (Tgf-β1,
Tgf-β2and Tgf-β3)when compared to wild type diaphragm muscle, while no differences were
found in the gastrocnemius muscle (Fig 5a). A significant decrease of myostatin (Mstn) was
detected in both muscles of SGCA- and SGCD-null mice when compared to wild type mice,
but this decrease was larger in diaphragm muscles. No significant differences were detected
between male and female SGCD-null mice. We also measured gene expression levels of myos-
tatin and TGF-β type II and type I receptors. Gender-specific differences in activin A receptor
type 2A and 2B (Acvr2a and Acvr2b) levels were detected in SGCD-null diaphragm muscle,
where males expressed significantly higher mRNA levels than females (Fig 5b). Additionally,
Acvr2awas significantly upregulated in male SGCD-null relative to wild type diaphragm mus-
cle. A significant upregulation of transforming growth factor beta receptor 2 (Tgfbr2) was
detected in both muscles of SGCA- and SGCD-null mice when compared to wild type mice.
Alk1 was upregulated in the gastrocnemius and diaphragm muscle of LGMD mice (Fig 5c).
Alk4, which was previously described as a specific myostatin type I receptor in muscles [21, 22]
was significantly increased in LGMD diaphragm muscle. Similar to Acvr2a and Acvr2b results,
SGCD-null males expressed significantly higher Alk4 levels than did females. Alk5 levels were
significantly higher in diaphragm of SGCA- and female SGCD-null mice compared to wild
type and male SGCD-null mice.
To summarize, skeletal muscles of both LGMD strains contained a higher number of small
regenerative fibers than did wild type mice, which was further confirmed by increased expres-
sion levels of myogenic genes. In addition, fibrotic and fat infiltrates had accumulated in
LGMD muscles. Male SGCD-null mice showed more severe cardiac fibrosis than did female
mice. Moreover, TGF- β signalling components were increased, while Mstn levels were
null mice showed a significant increase in collagen type I positive area compared to wild type. (c) Fibrotic and
inflammatory gene expression measured by qPCR, normalized to Gapdh (n = 5 mice per group) in skeletal
muscles of LGMD and wild type mice. A significant increase in Col1a1 and Cd68 expression was found in
SGCA- and SGCD-null muscles when compared to wild type muscles. (d) Immunofluorescence images of the
heart stained with collagen type I (fibrotic marker, green). Scale bar: 1000 μm. (e) The percentage of collagen
type I positive area, measured with Image J was significantly increased in SGCD-null mice compared to wild
type mice; males showed a significantly higher increase in collagen than did female SGCD-null mice. Q,
quadriceps; GC, gastrocnemius; TA, tibialis anterior; Dia, diaphragm. * Indicates a significant difference from
WT controls. # Indicates a significant difference from female SGCD-null mice. Error bars represent ± SD.
https://doi.org/10.1371/journal.pone.0182704.g003
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Fig 4. Accumulation of fat infiltrates in LGMD strains. (a) Immunofluorescent images of skeletal muscles
stained with Nile-red (infiltrated lipids, red) Scale bar: 100 μm (b) Quantification of the immunofluorescent
areas. A significant increase in Nile red -positive areas (n = 5 mice per group) was found in SGCD-null
diaphragm and SGCA-null gastrocnemius muscles when compared to wild type muscles. (c) Adipogenic gene
expression measured by qPCR, normalized to Gapdh (n = 5 mice per group). Upregulation of adipogenic
gene expression (Adipoq, Ppar-gamma, Atgl) was found in diaphragm muscle of both LGMD strains and Hsl
was significantly upregulated in SGCA-null diaphragm muscle compared to wild type. Q, quadriceps; GC,
gastrocnemius; TA, tibialis anterior; Dia, diaphragm. * Indicates significant difference from WT controls. Error
bars represent ± SD.
https://doi.org/10.1371/journal.pone.0182704.g004
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Fig 5. MSTN/TGF-β signalling contributes to LGMD disease pathology. (a) Gene expression analysis of three Tgf-β isoforms and Mstn.
Tgf-β1, Tgf-β2 and Tgf-β3 levels were significantly higher in diaphragm muscles of LGMD compared to wild type, while they did not differ in
gastrocnemius muscles. Mstn levels were significantly lower in gastrocnemius and diaphragm muscles of LGMD mice. (b) Gene expression
analysis of type II receptors Acvr2a, Acvr2b and Tgfbr2. Acvr2a levels were upregulated in male SGCD-null compared to wild type and
female SGCD-null diaphragm muscles. Acvr2b levels were significantly higher in diaphragm muscles of SGCD-null males compared to
females. Tgfbr2 expression was significantly increased in gastrocnemius and diaphragm muscles of LGMD compared to wild type mice. (c)
qPCR analysis of type I receptors: Alk1, Alk4 and Alk5. Alk1 levels were upregulated in LGMD gastrocnemius and SGCA- and male SGCD-
null diaphragm muscles compared to wild type muscles. Alk4 was significantly increased in diaphragm muscles of LGMD mice relative to
wild type. In addition, Alk4 levels were significantly lower in SGCD-null females than males. Alk5 was significantly higher in diaphragm
muscles of SGCA- and female SGCD-null mice relative to wild type and male SGCD-null mice. Data were normalized to Gapdh (all n = 5
mice per group). GC, gastrocnemius; Dia, diaphragm. * Indicates a significant difference from WT controls. # Indicates a significant
difference from male SGCD-null mice. Error bars represent ± SD.
https://doi.org/10.1371/journal.pone.0182704.g005
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downregulated in LGMD muscles. All these dystrophic hallmarks were most pronounced in
diaphragm muscle.
Functional test regime does not interfere with the muscle pathology. To assess whether
the functional test regime interfered with disease pathology in both LGMD strains, similar
sized sedentary groups were included. We measured muscle integrity, muscle physiology and
expression of genes involved in LGMD muscle pathogenesis in these mice. The functional test
regime did not interfere with muscle integrity in both LGMD strains, as CK levels were com-
parable between functional test regime and sedentary groups (Fig 6a). Moreover, the func-
tional test regime also did not affect physiology of tibialis anterior muscles (Fig 6b). Lastly,
gene expression levels did not differ between the groups, except for Mstn levels, which were
significantly decreased in functionally challenged compared to sedentary SGCA-null mice (Fig
6c).
Discussion
Currently, there is no therapy available for LGMD types 2D and 2F and clinical management
is similar to that described in care guidelines for DMD [19, 23]. A number of animal models of
α- and δ-sarcoglycanopathies have been developed with the aim to understand the mechanism
of disease pathogenesis and to identify therapeutic targets. Genetically engineered mice defi-
cient for either α-sarcoglycan (SGCA-null) or δ-sarcoglycan (SGCD-null) are suitable models
for pre-clinical research because they recapitulate many features of the human disease [7, 8].
However, the crucial elements for evaluation of drug benefits are still lacking, including com-
prehensive natural history data and clearly defined outcome measures. This hinders pre-clini-
cal research in LGMD mouse models. To address this shortcoming, we collected natural
history data and defined outcome measures for α- and δ–sarcoglycan deficient mice in the
present study.
Mice underwent longitudinal, non-invasive muscle function assessments in a reliable and
reproducible manner, as previously described for mdx mice [12], allowing us to monitor dis-
ease progression and treatment effects over time [24]. We found that the two and four limb
hanging tests were sensitive and reliable outcome measures, as we detected marked differences
in the results between wild type and both LGMD strains with high statistical significance.
Namely, we observed a significant muscle function impairment already at four weeks of age in
both LGMD strains, confirming previous findings that sarcoglycan deficient mice have an
early disease onset [25]. Moreover, these differences increased over time. Although, both
female and male SGCD-null mice fully manifest the disease phenotype, we found that there
were gender differences that influenced muscle function assessments of SGCD-null mice.
Therefore, we advise to use males for pre-clinical studies, or alternatively large equally sized
groups for each gender and treatment arm to minimize variation.
Results of the four limb grip strength test were significantly different between wild type and
SGCD-null mice, while this test was less effective for SGCA-null mice. We suggest using four
limb grip strength as an outcome measure, but only for SGCD-null mice. In contrast to both
hanging tests, the four limb grip strength test was ineffective in detecting a decline in muscle
function over time, thus this test is not useful for measuring disease progression.
We also identified functional assessments that are less useful. Rotarod testing analysis did
not reveal any significant differences in SGCA- and SGCD-null mice relative to wild type
mice. For mdx mice, limitations and possible optimizations of rotarod testing have been previ-
ously discussed [24]. There and here, high variability between individual mice did not permit
comparison between groups or across studies. We therefore propose to exclude rotarod testing
as an outcome measure for pre-clinical trials in LGMD mice. The beam walk test has been
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Fig 6. Functional test regime did not interfere with muscle pathology in both LGMD strains. (a) CK levels were similar
in functionally challenged and sedentary mice. (b) Tibialis anterior physiology of the functional challenged and sedentary
groups. The functional test regime did not have an effect on muscle physiology (c) Gene expression analysis of pathogenic
markers in gastrocnemius muscle of functionally challenged and sedentary LGMD mice. Myh3, Col1a1 and Cd68 mRNA
levels did not differ between functionally challenged and sedentary groups. Mstn levels were lower in functionally challenged
compared to sedentary SGCA-null mice. # Indicates a significant difference from non-functional SGCA-null mice. Error bars
represent in a, b ± SEM and in c ± SD.
https://doi.org/10.1371/journal.pone.0182704.g006
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used to assess motor skills in mice with cortical impact lesions [26] and in Huntington disease
mouse models [27, 28]. To our knowledge this test has never been performed in LGMD
strains. In this study, we observed an increase in traverse time and hind paw slips in LGMD
relative to wild type mice. However, these differences did not reach significance. We think that
the beam walk test is a reliable and sensitive measure for balance and coordination, but more
suitable in mouse models for nervous system disorders than muscular dystrophies.
CK levels are a widely used biomarker for fiber damage. Similar to LGMD patients, the sar-
coglycan-deficient mice showed elevated CK levels. However, CK is a very global measure of
muscle damage and tends to be variable based on e.g. animal activity [24]. Due to these limita-
tions, it is difficult to correlate the CK values to disease progression. Although we were able to
detect worsening of muscle function with age in LGMD mice, CK levels were highly elevated
but remained unchanged over time.
Respiratory dysfunction is observed in LGMD patients at an advanced stage of the disease
and is associated with reduced life expectancy [29]. Impairment in respiratory function was
also clearly detected in SGCA- and SGCD-null mice. Contrary to the human situation, we
observed a deficit already at an earlier stage.
We assessed specific and isometric force contraction in tibialis anterior muscles. Confirm-
ing our findings from non-invasive functional tests, these analyses showed a marked
impairment in muscle function and higher susceptibility to muscle damage in LGMD com-
pared to wild type mice. Such functional assessments are valuable tools for validation of muscle
function and treatment benefits.
We here show that active muscle regeneration persists in 34-week-old mice and thereby
may counteract progressive muscle loss. In contrast, muscle regeneration in older LGMD 2D
and 2F patients is impaired, leading to severe myopathy and premature death [6, 29, 30]. Fur-
thermore, we examined levels of fibrosis in LGMD mice using a collagen type I staining. We
detected marked differences between LGMD and wild type mice and between different mus-
cles. However, the method used here overestimates the amount of collagen in dystrophic mus-
cles, since collagen present in the endomysium (both in wild type and dystrophic muscles) is
included in the calculation. Moreover, we found that muscles of both LGMD strains contained
fat droplets, with the highest level in the diaphragm. Our finding concurs with the previous
electron microscopy study that found fat droplets in the diaphragm from SGCA-null mice
[31]. We think that it is a specific hallmark for sarcoglycan mutants, since to our knowledge it
has never been described in mdx mice and other muscular dystrophy mouse models [25]. His-
tological evaluation of fat droplets differed from the gene expression analyses of fat-related
genes, where fat droplets were mainly detected in gastrocnemius and diaphragm muscles,
while Ppar-gamma was upregulated in quadriceps and diaphragm muscle and Adipoq was
increased in tibialis anterior muscle. This discrepancy between histological and gene expres-
sion data can be explained by the fact that we could have lost fat droplets during the sectioning
procedure, as muscle was sectioned at -20˚C while fat is usually cut at lower temperature.
Currently, the muscle type used for histological examinations varies between laboratories
as there is no agreement about which muscle type best mimics the histological phenotype
observed in patients with LGMD. In our study, we compared quadriceps, gastrocnemius, tibia-
lis anterior and diaphragm muscles of SGCA- and SGCD-null mice. All muscle dystrophy hall-
marks examined were more pronounced in diaphragm muscles. Interestingly, this is in line
with a number of other muscular dystrophy mouse models [25]. The diaphragm is thought to
be the most frequently used muscle, which would explain the more severe contraction induced
damage. When we compared between limb muscles, the quadriceps and gastrocnemius were
affected to a similar extent, whereas the tibialis anterior muscle showed a milder phenotype.
Therefore, we conclude that there is a specific pattern of muscle type involvement in LGMD
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mice which needs to be taken into consideration in pre-clinical test designs. However, the
exact cause of this specific pattern remains unclear It has been shown that muscle fiber type
composition can influence disease progression. In DMD patients and mdx mice, the fast-gly-
colytic fibers are more susceptible to contraction induced damage and the first to degenerate,
whereas the slow-oxidative fibers are more protective against damage [32, 33]. This means that
fast muscles (e.g. extensor digitorum longus) are earlier and more severely affected by the dis-
ease than slow fiber-rich muscles (e.g. soleus) [34]. However, our studied limb muscles contain
comparable mixture of fiber types, mostly fast type IIb fibers. Thus, this cannot explain the
observed difference in disease severity between these muscles. Interestingly, the mild pheno-
type of tibialis anterior muscle was also observed in mdx mice when compared to other limb
muscles [11]. As mentioned previously for diaphragm, frequent muscle usage contributes to
more severe muscle damage. However, differences in usage of limb muscles and other factors
contributing to distinguished muscle type involvement remain to be further investigated.
Several members of the TGF- β and myostatin signalling pathways have been implicated as
therapeutic targets for a large group of neuromuscular disorders, including LGMD [20]. More-
over, activity of TGF- β signalling modifies the severity of disease pathology [35]. We conclude
that the diaphragm—being the more severely affected muscle and expressing higher levels of
TGF- β isoforms—provides a suitable model for studying how the TGF- β signalling mediates
the adverse effects on muscle pathology in LGMD mouse models. In contrast to TGF-β, myos-
tatin, a muscle-specific secreted peptide serving as muscle growth inhibitor [36], was decreased
in LGMD skeletal muscles. Furthermore, decrease in myostatin was associated with more
severe disease phenotype. Therefore, it is debatable whether myostatin inhibition will be bene-
ficial at an advanced stage of disease. In a previous study, early myostatin inhibition was bene-
ficial but this treatment had no therapeutic effect in older LGMD mice [37].
Since most parameters assessed remained unchanged between sedentary and functional
challenged groups, we concluded that the functional test regime did not interfere with the dis-
ease pathology. Notably, Mstn transcript levels were decreased in functionally challenged
SGCA-null mice. On one hand, we think that Mstn levels may be modulated by the functional
test regime, since myostatin is profoundly involved in whole body metabolism and training
results in a decreased myostatin expression [38]. On the other hand, it has been demonstrated
that Mstn expression was not affected by chronic treadmill exercise in mdx mice, which is
much more detrimental to the mice than the functional test regime that was used in the pres-
ent study [39]. We postulate that the effect on Mstn expression might be genotype-specific, as
it was only observed in SGCA-null mice. However, this needs to be further validated.
Cardiac involvement has been reported in 17% to 50% of patients with sarcoglycanopa-
thies [40]. SGCD-null mice, likewise develop cardiomyopathy with focal areas of fibrosis due
to abnormalities in the coronary vasculature (18). While SGCA-null mice display progressive
muscular dystrophy, but no cardiac abnormalities [9]. We indeed detected cardiac fibrosis in
SGCD-null but not in SGCA-null mice. The mechanisms underlying differences in patho-
genesis of cardiomyopathy between SGCA- and SGCD-null mice were previously reported
[8, 41, 42]. The main difference is that δ-sarcoglycan is strongly expressed in the smooth
muscle cells, in contrast to the α-sarcoglycan. Thus, the deficiency for δ-sarcoglycan in
SGCD-null mice results in loss of vascular smooth muscle complex leading to the disruption
of the coronary vasculature and the development of myocardial necrosis [8]. Interesting, we
found that cardiac fibrosis was more pronounced in males than in females, which positively
correlates with the performances in the limb hanging tests. We therefore would advise the
use of SGCD-null males in pre-clinical studies assessing therapeutic effects of cardioprotec-
tive drugs for LGMD 2F.
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Conclusion
Our study offers a comprehensive natural history dataset, based on which we made a list of rec-
ommendations to be considered in conducting pre-clinical experiments in SGCA- and SGCD-
null mice.
1. Age of treatment: We recommend to start treatment in both young mice (four weeks of
age) and in older mice (16 weeks of age). Since, muscle function is impaired at 4 weeks of
age and decline is detectable between 14–16 weeks of age.
2. Sample size: Sufficient numbers of mice must be included to detect statistically significant
differences. Based on our statistical analyses, we concluded that the exact numbers depend
on the variability of each outcome measure. Functional in vivo tests show higher variability
and should include at least six mice per group. Terminal outcomes such as histological and
gene expression analyses are less variable and require a minimum of five mice per group.
3. Gender selection: We advise to use SGCD-null males for pre-clinical trials, as they provide
a larger therapeutic window (see Results from the hanging tests and measured levels of car-
diac fibrosis). Although SGCA-null mice did not show any significant differences between
genders, we advise to use single gender (preferably males) for pre-clinical therapeutic trials
to minimize variation, or use large sample sizes of both genders.
4. Muscle selection: As different muscle types are not equally affected, we recommend to
include several different muscles in the treatment evaluation, e.g. diaphragm (as the most
severely affected muscle) and at least one of the limb muscles (quadriceps or
gastrocnemius).
5. Outcome measures: Functional in vivo tests such as hanging tests and whole-body plethys-
mography are informative for both LGMD strains, whereas grip strength tests are less appli-
cable to SGCA-null mice. We do not recommend the use of rotarod or beam walk tests.
Defined terminal outcome measures include specific and isometric force contraction
assessments in tibialis anterior muscles, histological analyses like fiber size distribution,
fibrosis and fat droplets and expression analyses of genes involved in muscle regeneration,
fibrosis, inflammation and adipogenesis.
Supporting information
S1 Fig. Experimental timeline. Grey squares indicate time points at which functional test
regime was performed. Black stars denote time points at which blood samples were collected
for CK measurements. Respiratory function was conducted in mice at 15 and 34 weeks of age
indicated by black circles. Muscle physiology and terminal analyses were performed at 34
weeks of age indicated by black square.
(TIF)
S2 Fig. Functional test performances of SGCA- and SGCD-null mice. (a) Normalized four
limb grip strength was significantly decreased in SGCD-null mice than in wild type and
SGCA-null mice (b) Maximum running time on the rotarod was shorter in both LGMD
strains when compared to wild type mice. SGCA-null mice performed worse than SGCD-
null mice in the rotarod test. (c) Maximum hanging time with two limbs was significantly
shorter in SGCA- and SGCD-null mice when compared to wild type mice. SGCD-null mice
performed better than SGCA-null mice did. (d) Maximum hanging time with four limbs
was significantly decreased in SGCA- and SGCD-null mice when compared to wild type
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mice. SGCD-null mice outperformed SGCA-null mice. (e) Traverse latency (seconds) was
higher and increased with age in SGCA- and SGCD-null compared to wild type mice.
(f) The number of hind limb slips was higher and increased with age in both LGMD strains
compared to wild type mice. (g) Body weights recorded over time for wild type, SGCA- and
SGCD-null mice.  Indicates a significant difference from wild type (WT) controls. # Indi-
cates a significant difference from SGCA-null mice. Error bars represent standard error of
the mean.
(TIF)
S1 Checklist. This file contains ARRIVE (Animal Research: Reporting of In Vivo Experi-
ments) guidelines checklist that is required for reporting of research using animals.
(DOCX)
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